# GlaxoSmithKline Dresden vaccine plant closure > Live situation record from CLSTR: https://clstr.news/situations/glaxosmithkline-dresden-vaccine-plant-closure > Updated: 2026-09-14T05:48:21.000Z. Sources: 10. Developments: 2. GlaxoSmithKline (GSK) has announced plans to close its vaccine manufacturing facility in Dresden, Germany, by mid-2028. The closure will end 115 years of production at the site, which was founded in 1911. The facility currently employs approximately 650 people and specializes in producing influenza and hepatitis vaccines, with a weekly output of about two million doses. GSK attributed the decision to declining global demand for traditional egg-based influenza vaccines and existing production overcapacity. The company intends to consolidate influenza vaccine production at its site in Sainte-Foy, Canada, while also noting a strategic shift toward mRNA technologies. The industrial union IG BCE and the local works council have pledged resistance to the closure. The union expressed concerns regarding the loss of highly specialized industrial jobs and critical pharmaceutical expertise in the Saxony region, noting that the local pharmaceutical industry has already seen the loss of 4,250 jobs. ## Timeline ### 2026-09-14: GlaxoSmithKline to close Dresden vaccine plant by 2028 GlaxoSmithKline will close its 115-year-old vaccine manufacturing plant in Dresden, Germany, by mid-2028, citing low global demand and excess capacity. Production will shift to Canada. 2 sources. https://clstr.news/cluster/glaxosmithkline-to-close-dresden-vaccine-plant-by-2028-1 ### 2026-09-10: GlaxoSmithKline to close Dresden vaccine plant by 2028 GlaxoSmithKline plans to close its Dresden vaccine plant by summer 2028, affecting 650 jobs, as production shifts to Canada due to declining demand for traditional influenza vaccines. 8 sources. https://clstr.news/cluster/glaxosmithkline-to-close-dresden-vaccine-plant-by-2028 --- Cite as: GlaxoSmithKline Dresden vaccine plant closure. CLSTR, https://clstr.news/situations/glaxosmithkline-dresden-vaccine-plant-closure